Search Results (2,512)

Pancreatic ductal adenocarcinoma (PDAC) is characterized by poor clinical outcomes and limited responsiveness to conventional treatments. Beyond delayed diagnosis, its high mortality is linked to limited treatment choices and resistance to chemotherapy. Neoplastic cells characterized by stem-like features and epithelial–mesenchymal transition (EMT) activation are crucial drivers of drug resistance and metastatic progression. Consequently, targeting these cellular programs could represent a promising therapeutic strategy for PDAC. N-acetyl-L-aspartic acid (NAA) is an endogenous metabolite, mainly localized in the central nervous system, where it facilitates acetate storage for lipid metabolism. Previous studies established its antineoplastic effect in neuroblastoma, promoting a more differentiated phenotype of cancer cells. Here we investigated the effects of NAA on BxPC-3 pancreatic cancer cells using both 2D and 3D models. NAA treatment induced a dose-dependent reduction in cell proliferation and led to a significant downregulation of stemness-associated surface markers, with concomitant upregulation of E-cadherin. Furthermore, NAA significantly enhanced cellular radiosensitization with a reduction in caveolin-1 and increased efficacy of gemcitabine in PDAC cells. Collectively, these results confirmed the anticancer activity of NAA and provide a rationale for further investigation of its synergistic effects with radiotherapy to yield better PDAC treatments. Full article

Hypoxia is a hallmark of the tumor microenvironment. Under hypoxia, HIF-1$\alpha$ accumulates and promotes both epithelial–mesenchymal transition (EMT) and glycolysis depending on glucose levels. However, how EMT and glycolysis are coordinated by oxygen and glucose abundance is still not well understood. Here, we developed an integrated model to investigate the mechanism underlying the regulation of EMT and glycolysis at varying oxygen and glucose levels. We focused on how the interplay between EMT and glycolysis maintains cell phenotypes. Our results show that hypoxia and sufficient glucose facilitate the transition of cells toward an invasion-associated mesenchymal–glycolytic phenotype. Moreover, enhanced glycolysis promotes the completion of EMT and reinforces the intermediate states. Under glucose-sufficient conditions, the reciprocal promotion between EMT and glycolysis may convert transient hypoxia into persistent mesenchymal memory that maintains the mesenchymal phenotype after reoxygenation. Our work clarifies how metabolic microenvironmental fluctuations are transformed into durable invasion-associated phenotypic states. Our work may provide insights into therapies that target both the EMT and glycolysis pathways. Full article

Non-small cell lung cancer is one of the leading causes of cancer-related mortality. The effectiveness of treatment is limited by several factors, including significant tumoral heterogeneity, rapid development of drug resistance, high metastatic potential, and a complex tumor microenvironment. In recent years, natural products have emerged as valuable resources for the discovery of novel antitumor strategies against non-small cell lung cancer. These compounds possess diverse chemical properties, target multiple pathways, are abundant in nature, and exhibit relatively low toxicity. The utilization of existing medications with established pharmacokinetic profiles and safety records, combined with shorter development timelines, shows promise for advancing lung cancer treatment research. A growing body of evidence indicates that both naturally occurring compounds and commercially available drugs exert effects that extend beyond traditional cytotoxic mechanisms. These agents influence processes such as ferroptosis, oxidative stress, metabolic reprogramming, autophagy, apoptosis, epithelial–mesenchymal transition (EMT), tumor immune microenvironments, and epigenetic networks, suggesting that their activities can be leveraged for a robust multi-target antitumor strategy. Accordingly, this review summarizes research advances on natural products and repurposed marketed drugs for non-small cell lung cancer; outlines their potential for combination with chemotherapy, targeted therapy, radiotherapy and immunotherapy; and discusses future directions for clinical translation. Full article

Background & Aims: Signaling within the tumor microenvironment (TME) emerges from dynamic crosstalk among cancer cells, host tissues, and the microbiome. Orthotopic and ectopic xenograft models are widely used in preclinical liver cancer research, yet it remains unclear to what extent tumor location shapes systemic host responses and gut–liver communication. We therefore investigated how anatomical context influences host transcriptomes and spatially resolved intestinal microbial ecosystems in hepatoblastoma (HB). Methods: We integrated bacterial/archaeal ecology with host and xenograft transcriptomes in orthotopic versus ectopic hepatoblastoma xenografts in male athymic CAnN.Cg-Foxn1nu/Crl mice. Single-sample GSEA, sparsity-aware networks, and DIABLO multi-block integration mapped pathway-level coordination across intestinal segments, stool, secondary lymphoid organs, livers, and tumors. Results: Tumor localization was associated with compartment-specific differences in host signaling, with the mesenteric lymph node and liver showing prominent shifts in TNFA/NF-κB, hypoxia, unfolded protein response, xenobiotic metabolism, mTORC1, KRAS, epithelial–mesenchymal transition, and MYC/E2F cell-cycle axes. Archaea exhibited pronounced, niche-specific signatures that showed positive correlations with proliferative and inflammatory Hallmarks and negative correlations with interferon pathways. Multi-omics integration (r ≥ 0.85) indicated coordinated variation linking specific microbial families to host and tumor programs and positioned the xenograft block as a hub connecting EMT, mTORC1, and angiogenesis to defined archaeal and bacterial taxa. Conclusions: Tumor topography remodels TME signaling through compartment-dependent host–microbiome–tumor crosstalk, with archaeal domains emerging as salient correlates of proliferative and stress-response networks. These findings provide a systems framework and testable hypotheses for therapeutic modulation of TME signaling via interkingdom interactions. Full article

Background/Objectives: Gastric cancer (GC) remains a leading cause of cancer-related mortality, with metastasis being the primary driver of poor prognosis. The extracellular matrix glycoprotein tenascin-C (TNC) is implicated in tumor progression and metastasis, yet its regulatory mechanisms in GC remain poorly understood. Here, we identify RNA N6-methyladenosine (m6A) demethylase fat mass and obesity-associated protein (FTO) as a key modulator of TNC expression, promoting epithelial–mesenchymal transition (EMT) and GC metastasis. Methods: Integrating The Cancer Genome Atlas Stomach Adenocarcinoma (TCGA-STAD) and Gene Expression Omnibus (GEO) datasets (GSE246567, GSE181840, GSE163126, GSM4837878), we demonstrate that TNC is significantly upregulated in GC and correlates with worse clinical outcomes. Functional assays both in vitro and in vivo reveal that TNC knockdown suppresses GC cell proliferation, migration, invasion, and tumor metastasis, while overexpression of TNC rescues these effects. Mechanistically, FTO selectively demethylates TNC mRNA, reducing m6A modification at the 3’ untranslated region, thereby enhancing TNC mRNA stability and expression. RNA pull-down assays identify YTH domain family protein 2 (YTHDF2) as the m6A reader that recognizes the methylated site on TNC 3’UTR, and YTHDF2 knockdown partially rescues TNC expression and stability upon FTO loss. m6A RNA immunoprecipitation (MeRIP) and dual-luciferase reporter assays confirm FTO’s direct regulation of TNC via m6A demethylation. Furthermore, TNC promotes EMT by activating the phosphoinositide 3-kinase (PI3K)-AKT (protein kinase B) signaling pathway, as demonstrated by rescue experiments using the AKT activator SC79 and the PI3K inhibitor LY294002. Results: High FTO and TNC expression levels in clinical tissue samples correlate with poor patient survival. Conclusions: These findings reveal that the FTO/TNC/EMT axis represents a previously unrecognized epigenetic mechanism driving GC metastasis and suggest that targeting FTO-mediated m6A modification may provide a novel therapeutic strategy for GC patients with high metastatic potential. Full article

Background/Objectives: Congenital anomalies of the kidney and urinary tract (CAKUT) are a leading cause of pediatric kidney disease. Epithelial–mesenchymal transition (EMT), governed by SNAI1 and TGF-β, and a vascular–mesenchymal program marked by PECAM1 and VIM are central to nephrogenesis, but whether these programs are transcriptionally activated in human CAKUT is unknown. We assessed their expression and spatial organization in human fetal kidneys. Methods: We reanalyzed public transcriptomic datasets for six transcripts (SNAI1, TGFB1–3, PECAM1, VIM) and performed quantitative double immunofluorescence for four gene products (SNAIL, TGF-β1, CD31, vimentin) on formalin-fixed human fetal kidneys (20 controls, 19 CAKUT), with colocalization quantified by Pearson’s coefficient. Results: No statistically significant difference in transcript or protein abundance was detected between control and CAKUT kidneys, in either the cortex or the medulla, and abundance did not change across developmental phases. In contrast, spatial colocalization of SNAIL–TGF-β and of CD31–vimentin was increased in CAKUT kidneys. Conclusions: These findings may suggest that, in human fetal CAKUT, EMT and vascular–mesenchymal programs are not quantitatively upregulated but instead show altered spatial organization of otherwise unchanged gene products. As colocalization reflects spatial proximity rather than molecular interaction, these observations are correlative and warrant functional validation. Full article

Background: Prostate cancer (PCa) is a leading cause of cancer-related mortality worldwide, highlighting the need for improved prognostic tools. The integration of artificial intelligence (AI) and machine learning (ML) with multi-omics data offers new opportunities for biomarker discovery and risk stratification. Methods: We integrated bulk transcriptomic data from GSE116918 (training, n = 248) and three cross-cohort consistency evaluation cohorts (TCGA-PRAD, GSE70769, GSE46602), focusing on 1087 epithelial–mesenchymal transition (EMT)-associated genes. Using consensus clustering, weighted gene co-expression network analysis (WGCNA), and 91 machine learning algorithm combinations (including Random Forest, Lasso, and CoxBoost), we constructed a prognostic signature. SHAP analysis was used for model interpretability. Single-cell RNA sequencing (scRNA-seq, GSE268307, 10,672 cells) and spatial transcriptomics (10× Genomics Visium FFPE) provided hypothesis-generating evidence; spatial analysis was based on one tissue section. Results: A three-gene signature (INHBA, FAP, ITGBL1) effectively stratified patients into high- and low-risk groups, with the high-risk group showing significantly worse metastasis-free survival (HR = 1.61, 95% CI: 1.39–1.87; 4-year AUC = 0.93 in the training cohort; external AUCs ranged from 0.62 to 0.77). CytoTRACE inferred high differentiation potential of COMP+ fibroblasts, and Monocle3 inferred a transcriptional transition from COMP+ toward NELL2+ fibroblasts. BayesPrism deconvolution suggested that high inferred COMP+ fibroblast abundance was associated with poor prognosis and advanced T stage. NicheNet analysis prioritized BMP7 as a key upstream ligand, with downstream targets enriched in TGF-β signaling and stem cell pluripotency pathways. Conclusions: This study presents a machine learning-based multi-omics framework for prostate cancer risk stratification. The three-gene signature provides a new exploratory prognostic model while inferring a COMP+ to NELL2+ transcriptional transition. These findings may inform future hypothesis-driven studies of treatment sensitivity, pending experimental validation, and demonstrate the value of AI-driven multi-omics integration for precision oncology. Full article

Background/Objectives: Colorectal cancer (CRC) remains a major cause of cancer-related mortality worldwide, largely owing to metastasis, recurrence, and resistance to conventional therapies. Natural-product-derived compounds represent an important source of anticancer drug candidates. This study investigated the anticancer activity of purified narciclasine, which was tentatively annotated as a major detected constituent of Lycoris sanguinea extract, and examined its association with HELLS-associated DNA damage responses in CRC cells. Methods: Human CRC cell lines HT29 and HCT116 were used to evaluate the cytotoxic and mechanistic effects of L. sanguinea extract and narciclasine. Cell viability, clonogenic growth, apoptosis, mitochondrial membrane potential, cell cycle distribution, migration, and invasion were assessed. Western blotting was performed to analyze apoptosis-, cell cycle-, epithelial–mesenchymal transition (EMT)-, and DNA damage-related proteins. UPLC-QTOF/MS analysis was used to identify major phytochemical constituents. HELLS knockdown and γ-H2AX immunofluorescence staining were conducted to examine the involvement of HELLS in narciclasine-associated DNA damage and apoptosis. Results: L. sanguinea extract reduced CRC cell viability, suppressed clonogenic growth, induced mitochondrial dysfunction and caspase-dependent apoptosis, and promoted G2/M cell cycle arrest with decreased cyclin B1 and increased p53/p21 expression. The extract also inhibited migration and invasion, accompanied by reduced β-catenin, N-cadherin, vimentin, slug, and snail expression and increased E-cadherin expression. UPLC-QTOF/MS tentatively annotated narciclasine as a major detected constituent. Purified narciclasine recapitulated several anticancer effects of the extract, accompanied by HELLS downregulation, increased γ-H2AX accumulation, reduced cyclin B1 expression, and enhanced PARP and caspase-3 cleavage. HELLS knockdown further sensitized CRC cells to narciclasine-associated γ-H2AX accumulation, G2/M arrest-associated signaling, and apoptosis. Conclusions: Narciclasine treatment was associated with HELLS downregulation, DNA damage-associated signaling, G2/M cell cycle arrest-associated changes, EMT suppression, and apoptosis in CRC cells. These findings suggest that narciclasine is a promising natural-product-derived lead compound for further preclinical evaluation in HELLS-associated CRC vulnerabilities. Full article

Breast cancer is a highly heterogeneous malignancy that remains one of the leading causes of cancer-related mortality among women worldwide. Despite significant advances in breast cancer research and therapy, disease heterogeneity, treatment resistance, and metastatic progression remain major obstacles to effective disease management. Among the molecular regulators involved in breast cancer, microRNAs (miRNAs) have been recognized as critical post-transcriptional regulators of gene expression, functioning as either oncogenes or tumor suppressors. By modulating the expression of target RNAs, miRNAs control key biological processes involved in tumor initiation and progression, including cell proliferation, apoptosis, angiogenesis, epithelial–mesenchymal transition (EMT), invasion, and metastasis. To investigate miRNA function and explore their therapeutic potential, a wide range of approaches have been developed to modulate miRNA expression. These include gain-of-function strategies, like miRNA mimics, miRNA expression vectors, and CRISPR activation (CRISPRa), as well as loss-of-function approaches, including anti-miRNA oligonucleotides (AMOs), miRNA sponges, CRISPR-Cas9-mediated gene knockout, and CRISPR interference (CRISPRi). This review provides a comprehensive overview of the biological roles of miRNAs in breast cancer and discusses current technologies for miRNA modulation, their molecular mechanisms, experimental and therapeutic applications, and associated limitations. In addition, it summarizes recent advances in miRNA delivery systems, including viral vectors, organic nanoparticles, and inorganic nanocarriers, highlighting their potential to improve delivery efficiency, target specificity, and facilitate clinical translation. Finally, the review discusses future perspectives, emphasizing the transition from single-target interventions toward network-level regulation and the integration of miRNA-based strategies into precision oncology to support the development of more effective breast cancer therapies. Full article

Background: As a member of the T-box transcription factor family, TBX18 was found to be involved in ESCC progression, while its role in regulating radiotherapy resistance in ESCC remains unclear. This study was designed to investigate the molecular mechanisms underlying the regulation of radioresistance in ESCC by TBX18. Methods: Sphere formation assay, Transwell invasion assay, and wound healing assay were conducted to show the influence of TBX18 on tumor stemness and epithelial–mesenchymal transition (EMT). Western blot, immunofluorescence, chromatin immunoprecipitation-qPCR (ChIP-qPCR) and dual-luciferase reporter assay were preformed to identify regulatory networks. A nude mouse xenograft tumor model was established to assess the regulatory effect of TBX18 and SIX1 on radioresistance of ESCC in vivo. Results: TBX18 expression was positively associated with stemness markers, including CD44, CD271, and SOX2. TBX18 promoted stemness-associated phenotypes, EMT, migration, invasion, and radioresistance in ESCC cells. Mechanistically, TBX18 directly bound to the SIX1 promoter and transcriptionally activated SIX1 expression. In turn, SIX1 enhanced TBX18 protein stability by suppressing ubiquitin–proteasome-mediated degradation, thereby forming a positive feedback loop. Functional rescue experiments demonstrated that the TBX18/SIX1 axis coordinately maintained stemness and EMT phenotypes and attenuated radiotherapy-induced apoptosis. In vivo studies further confirmed that TBX18 knockdown enhanced radiosensitivity, whereas SIX1 overexpression partially reversed this effect. In addition, immunohistochemical analysis revealed that TBX18 and SIX1 were significantly upregulated in ESCC tissues and positively correlated with each other. Full article

Therapy resistance remains a major cause of cancer-related mortality. Cisplatin (cis-diamminedichloroplatinum, CDDP) is a first-line chemotherapeutic agent for oral cancer, but intrinsic and acquired resistance substantially limit its clinical efficacy. Epithelial–mesenchymal transition (EMT) has been associated with drug resistance across multiple tumor types; however, its involvement in cisplatin resistance in oral cancer remains incompletely understood. Here, we established an in vitro model of cisplatin resistance using the squamous cell carcinoma 9 (SCC-9) cell line and generated two populations with distinct resistance levels. We observed morphological and transcriptional changes consistent with EMT-related features, including increased mRNA expression of Vimentin, SNAIL1, ZEB1, ZEB2, and CDH2. Resistant cells also exhibited reduced proliferation, whereas the intermediately resistant population, cisplatin-resistant 4 (CPR4), showed greater wound closure, suggesting enhanced migratory behavior and features consistent with a hybrid-like EMT state. Conversely, the more resistant subline, cisplatin-resistant 8 (CPR8), exhibited a more stationary phenotype. Transcriptomic profiling by RNA sequencing (RNA-seq) revealed extensive differential gene expression associated with EMT and cisplatin resistance. Functional enrichment analyses identified Gene Ontology (GO) terms related to cell adhesion, extracellular matrix organization, and calcium ion binding, while Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis revealed enrichment of PI3K/Akt signaling. Together, our findings support a dynamic model in which distinct EMT-related transcriptional states are associated with different levels of cisplatin resistance. This study provides insights into transcriptional changes associated with resistance acquisition and highlights candidate genes and pathways for further investigation and functional validation in oral cancer. Full article

Background: The efficacy of chemotherapy in triple-negative breast cancer (TNBC) is limited by intrinsic resistance and the tumor microenvironment (TME). Accumulating evidence reveals a mechanistic connection between programmed death-ligand 1 (PD-L1) and c-x-c motif chemokine receptor 4 (CXCR4), which dominate stroma barriers, immune escape, and cancer metastasis. Earlier studies have shown that dual suppression of c-x-c motif ligand 12 (CXCL12)/CXCR4 and programmed cell death-1 (PD-1)/PD-L1 pathways regulates extracellular matrix (ECM) deposition, activation of cancer-associated fibroblasts (CAFs), and epithelial–mesenchymal transition (EMT) of pancreatic cancer cells. Methods: We combined BsNb PX4, a bispecific nanobody targeting PD-L1 and CXCR4, with paclitaxel or gemcitabine in multiple tumor cell lines and human peripheral blood mononuclear cell (hPBMC)-reconstituted xenograft mouse models. Antitumor activity was assessed by CCK-8, flow cytometry, and ELISA, and immune cell infiltration and TME remodeling were examined by immunofluorescence, immunohistochemistry, cytokine assays, and RNA-seq. Results: In MDA-MB-231 cells, BsNb PX4 synergistically enhanced paclitaxel-induced growth inhibition and apoptosis via G₂/M cycle arrest. This combinatorial strategy profoundly remodeled tumor immunity by expanding CD8⁺ T cells and depleting Foxp3⁺ CD4⁺ regulatory T cells (Tregs), while concurrently restoring T-cell cytotoxicity and skewing the cytokine balance toward an antitumor state, with elevated IFN-γ and reduced TGF-β1. Notably, compared with paclitaxel monotherapy, the combination significantly elevated intratumoral CD8⁺ T-cell infiltration, decreased Treg abundance, and exerted robust inhibitory effects on tumor growth and metastasis in humanized TNBC xenografts. Conclusions: These findings reveal that dual blockade of PD-L1 and CXCR4 acts synergistically with chemotherapy by triggering tumor cell apoptotic effects and reversing the immunosuppressive microenvironment, thereby emerging as a promising therapeutic strategy for TNBC. Full article

Metastasis-associated protein 1 (MTA1), an oncogenic transcriptional regulator, is overexpressed in canine urothelial carcinoma (UC) and is associated with aggressive clinicopathological features. However, its functional role and molecular mechanisms in canine UC remain poorly understood. Here, we investigated the contribution of MTA1 to epithelial-to-mesenchymal transition (EMT) and its interaction with BRAF signaling. MTA1 silencing in two canine UC cell lines significantly inhibited cell proliferation, cell survival, migration, and xenograft tumor growth. Mechanistically, MTA1 knockdown reduced the expression of MTA2, MTA3, and COX2, while producing unexpected changes in key EMT regulators, including Snail, Slug, and Cyclin D1, suggesting the activation of compensatory signaling pathways. MTA1 silencing also decreased mutant BRAF expression in AxA cells while increasing wild-type BRAF expression in SH cells, indicating context-dependent regulation of BRAF signaling. In AxA cells, reduced AKT phosphorylation following MTA1 knockdown further supports functional crosstalk between the BRAF and MTA1/AKT signaling pathways. Collectively, these findings identify MTA1 as a critical regulator of canine UC progression and reveal complex signaling interactions that support its potential as a therapeutic target for canine UC. Full article

Background: External and internal forces and tissue energy influence the structure and function of mammalian tissues during life in a gravitational field. Changing force (stress) and energy equilibria provide a dynamic means to regulate cell and tissue growth during development and maturation. However, genetic mutations and changes in expression of macromolecules involved in cell and extracellular matrix (ECM) equilibria lead to tumor formation. Methods: A model is presented illustrating connections between ECM, cell membranes, cell cyto- and nucleoskeletons, cell nucleus, and cell–cell junctions that promote energy storage, transmission, and dissipation. The effects of mutations involving changes in P53 and Coll 11A1 genes and changes in expression of collagens and collagen receptors, integrins, ILK, FAK, Talin, Paxillin, Kindlins, c-SRC, Actin, myosin light chain, Filamin A, E-cadherin, and beta catenin that have been reported to occur in cancerous lesions are examined. Results: When mutations or altered component expressions occur, mechanotransduction pathways are activated that lead to modified epithelial–mesenchymal (EMT) and endothelial–mesenchymal (ENT) transitions resulting in new cell division and deposition of ECM. Conclusions: It is hypothesized that changes in genes and expression of proteins in the connections between ECM and bound cells alter energy storage and dissipation. This leads to local stress concentrations that alter force and energy dynamic equilibria required to maintain homeostasis. Excess energy associated with broken connections within cells is dissipated through changes in myosin structure and function. Full article

Zoonotic bacterial pathogens are transmitted through various routes and are traditionally associated with acute febrile illnesses that may include pulmonary complications. However, in some survivors, the disease extends beyond the acute phase, leading to the remodeling of pulmonary architecture and driving progressive fibrosis. Although no direct cases have been reported, these pathogens may plausibly predispose injured lungs to carcinogenesis, similar to the well-recognized phenomenon of tuberculosis-associated scar cancer. As such long-term sequelae remain largely overlooked in current clinical practice, their potential contribution to fibrotic and malignant lung disease represents a critical and underexplored knowledge gap. This review proposes a unified mechanistic framework linking acute pathogen-mediated alveolar damage to chronic pulmonary fibrosis and subsequent lung carcinogenesis. We delineate four convergent biological pillars driving this continuum: (1) pathogen persistence establishing chronic Interleukin-1β (IL-1β)/Tumor necrosis factor-α (TNF-α)-mediated inflammation; (2) sustained TGF-β signaling and mechanotransduction driving progressive extracellular matrix remodeling; (3) unresolved reactive oxygen species (ROS) generation causing profound oxidative DNA damage; and (4) aberrant epithelial–mesenchymal transition (EMT) that perpetuates fibrosis and generates pre-malignant cell populations. Together, these sequelae alter lung biomechanics, suppress local immune surveillance, and create a mutagenic environment that is highly conducive to malignant transformation. Although direct epidemiological data is still emerging, the significant mechanistic overlap with idiopathic pulmonary fibrosis (IPF) presents a compelling rationale for shared oncogenic risk. We advocate for a paradigm shift in clinical practice, emphasizing the potential value of long-term surveillance for survivors of severe pulmonary infections. By integrating infectious diseases, pulmonology, and oncology, this framework highlights a neglected cause of fibrotic lung disease and establishes a foundation for future translational research. Full article